sc 51089 has been researched along with tetraethylammonium in 1 studies
| Studies (sc 51089) | Trials (sc 51089) | Recent Studies (post-2010) (sc 51089) | Studies (tetraethylammonium) | Trials (tetraethylammonium) | Recent Studies (post-2010) (tetraethylammonium) |
|---|---|---|---|---|---|
| 41 | 1 | 19 | 3,877 | 10 | 298 |
| Protein | Taxonomy | sc 51089 (IC50) | tetraethylammonium (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Mus musculus (house mouse) | 0.54 | |
| Solute carrier family 22 member 2 | Mus musculus (house mouse) | 3.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baloch, M; Clapp, LH; Hall, S; Turcato, S | 1 |
1 other study(ies) available for sc 51089 and tetraethylammonium
| Article | Year |
|---|---|
Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost.
Topics: Animals; Antineoplastic Agents; Calcium; Dose-Response Relationship, Drug; Endothelium, Vascular; Epoprostenol; Guinea Pigs; Hydrazines; Iloprost; Isoproterenol; Male; Muscle, Smooth, Vascular; Oxazepines; Phenylephrine; Potassium Channel Blockers; Potassium Channels; Prostaglandin Antagonists; Tetraethylammonium; Vasodilation; Vasodilator Agents | 1998 |